The Pioneer Fund Podcast

Pioneer Future Of Health & YC W26: The AI Health Tech Moment

40 min · 6 de abr de 2026
Portada del episodio Pioneer Future Of Health & YC W26: The AI Health Tech Moment

Descripción

In this episode, Jason Gray (Founder and General Partner, Pioneer Fund) and Dave Messina (General Partner, Pioneer Future of Health Fund) dive deep on the W26 Y Combinator batch and discuss key insights related to the Future of Health Fund coming out of one of the strongest biotech and health tech cohorts in recent history. The conversation covers how AI is reshaping drug discovery, replacing animal models with human biology representations, and acting as a co-pilot for scientists. From AI-powered primary care and revenue cycle automation to chronic disease management and elder care, they break down where they're seeing the most exciting founder activity — and what separates the companies worth backing from the AI wrappers that won't last. Plus: a look at one of Pioneer's standout portfolio exits — a psychedelics platform that sold its lead asset for over $1 billion after pioneering treatment-resistant depression therapy.

Comentarios

0

Sé la primera persona en comentar

¡Regístrate ahora y únete a la comunidad de The Pioneer Fund Podcast!

Prueba gratis

Empieza 7 días de prueba

$99 / mes después de la prueba. · Cancela cuando quieras.

  • Podcasts solo en Podimo
  • 20 horas de audiolibros al mes
  • Podcast gratuitos

Todos los episodios

2 episodios

episode Pioneer Future Of Health & YC W26: The AI Health Tech Moment artwork

Pioneer Future Of Health & YC W26: The AI Health Tech Moment

In this episode, Jason Gray (Founder and General Partner, Pioneer Fund) and Dave Messina (General Partner, Pioneer Future of Health Fund) dive deep on the W26 Y Combinator batch and discuss key insights related to the Future of Health Fund coming out of one of the strongest biotech and health tech cohorts in recent history. The conversation covers how AI is reshaping drug discovery, replacing animal models with human biology representations, and acting as a co-pilot for scientists. From AI-powered primary care and revenue cycle automation to chronic disease management and elder care, they break down where they're seeing the most exciting founder activity — and what separates the companies worth backing from the AI wrappers that won't last. Plus: a look at one of Pioneer's standout portfolio exits — a psychedelics platform that sold its lead asset for over $1 billion after pioneering treatment-resistant depression therapy.

6 de abr de 202640 min